Intercept Pharmaceuticals is a biopharmaceutical company that develops and sells therapeutics for non-viral liver diseases. Its main product is Ocaliva, used to treat primary biliary cholangitis along with other upcoming indications. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. for bezafibrate development and commercialization in the USA.